Key Highlights
- Dr. Chris Boshoff to lead Pfizer’s R&D from January 2025, succeeding Dr. Mikael Dolsten.
- Roger Dansey named Interim Chief Oncology Officer, with Johanna Bendell joining as Chief Development Officer, Oncology.
- Dr. Boshoff’s legacy includes delivering 24 approved medicines in over 30 indications.
Source: Business Wire
Notable Quotes
- “Chris has a compelling vision for the future of R&D at Pfizer…Under Chris’ leadership, Oncology has become one of Pfizer’s most productive divisions.” — Dr. Albert Bourla, Chairman and CEO at Pfizer
- “I am honored to be succeeding Mikael…I am confident that we can build on our long history of successes and drive even deeper focus on advancing impactful programs.” — Dr. Chris Boshoff, Chief Scientific Officer & President of R&D at Pfizer
SoHC's Take
This transition represents a pivotal moment for Pfizer’s R&D trajectory. Dr. Chris Boshoff’s extensive experience and proven track record in oncology and rare disease development position him as an ideal leader to accelerate Pfizer’s pipeline innovation. Under his leadership, the company is well-poised to maintain its competitive edge in oncology while broadening its impact across therapeutic areas. Dr. Johanna Bendell’s addition further underscores Pfizer’s strategic investment in oncology expertise, reinforcing its commitment to addressing high unmet medical needs globally.
